What service do you need? Contact Request

NCT07293351

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

← Clinical trials hub

Registry fields

Overall status: RECRUITING
Conditions: Advanced Renal Cell Carcinoma (RCC)
Study type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: Pumitamig, Ipilimumab, Cabozantinib, Casdatifan
Lead sponsor: Bristol-Myers Squibb (INDUSTRY)

Cached at: 2026-10-24 01:14:51

View on ClinicalTrials.gov

Brief summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with other agents in participants with advanced Renal Cell Carcinoma (RCC)

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report

Contact Support